This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eisai 미래 성장

Future 기준 확인 4/6

주요 정보

25.1%

수익 성장률

25.6%

EPS 성장률

Pharmaceuticals 수익 성장	21.8%
매출 성장률	9.1%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	28 Feb 2023

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

MUN:EII0 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (JPY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2025	846,893	74,892	72,454	94,043	12
3/31/2024	770,224	51,301	58,492	84,345	13
3/31/2023	745,981	60,303	64,984	113,396	13
12/31/2022	737,098	26,705	-17,149	18,648	N/A
9/30/2022	752,500	32,233	-8,913	30,329	N/A
6/30/2022	741,594	32,690	94,326	135,806	N/A
3/31/2022	756,226	47,954	77,123	117,590	N/A
12/31/2021	712,935	57,311	85,128	124,927	N/A
9/30/2021	691,250	62,508	80,215	123,618	N/A
6/30/2021	679,253	59,855	8,589	49,533	N/A
3/31/2021	645,942	42,119	35,709	73,853	N/A
12/31/2020	707,888	93,682	52,352	95,670	N/A
9/30/2020	713,400	120,571	77,080	112,990	N/A
6/30/2020	707,203	124,523	81,101	116,904	N/A
3/31/2020	695,621	121,767	52,556	102,782	N/A
12/31/2019	661,646	96,659	21,665	72,461	N/A
9/30/2019	631,974	57,725	12,273	62,240	N/A
6/30/2019	643,531	72,747	38,725	87,299	N/A
3/31/2019	642,834	63,386	76,092	103,714	N/A
12/31/2018	627,367	63,714	151,104	171,330	N/A
9/30/2018	625,106	65,679	167,298	186,973	N/A
6/30/2018	611,499	54,347	145,007	165,689	N/A
3/31/2018	600,054	51,845	124,916	149,649	N/A
12/31/2017	569,814	29,048	42,233	72,041	N/A
9/30/2017	554,276	30,269	33,537	61,644	N/A
6/30/2017	544,027	29,425	49,931	76,929	N/A
3/31/2017	539,097	39,358	55,850	75,851	N/A
12/31/2016	530,696	55,031	62,558	76,725	N/A
9/30/2016	542,313	71,812	N/A	78,627	N/A
6/30/2016	545,602	69,227	N/A	69,710	N/A
3/31/2016	547,922	54,933	N/A	95,617	N/A

애널리스트 미래 성장 예측

수입 대 저축률: EII0's forecast earnings growth (25.1% per year) is above the savings rate (0.2%).

수익 vs 시장: EII0's earnings (25.1% per year) are forecast to grow faster than the German market (10.2% per year).

고성장 수익: EII0's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: EII0's revenue (9.1% per year) is forecast to grow faster than the German market (3.4% per year).

고성장 수익: EII0's revenue (9.1% per year) is forecast to grow slower than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if EII0's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Eisai 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견